Biognosys Presenting Data on its TrueDiscovery™ and TrueTarget™ Proteomics Platforms at the AACR Annual Meeting 2022
31.3.2022 15:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the details of its presence at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held April 8-13, 2022, both in person in New Orleans, US and virtually. The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery™ and TrueTarget™. Additionally, Biognosys contributed to a poster that will be presented by its collaborator, NeoGenomics.
“The proteome contains a wealth of information about health and disease, and mass spectrometry-based proteomics has great potential in uncovering that information,” commented Lukas Reiter, Ph.D., Chief Technology Officer at Biognosys. “Our AACR data shows how Biognosys has been able to establish mass spectrometry-based proteomics technology to provide detailed and unbiased insights about the proteome. We illustrate how we’ve been able to increase efficiency and scalability at every step of the process. Moreover, we’re showcasing data we’ve generated with our collaborators that demonstrate the practical application of our platforms across all stages of research and drug development, from discovery to clinical settings.”
Biognosys will also be present with a team of scientific experts at booth #885.
Talk Details
-
Abstract 2136: Prediction of small molecule-protein binding events for BRD4 and EGFR inhibitors using HR-LiP, a novel structural proteomics approach
- Presenter: Yuehan Feng, Ph.D.
- Collaborator: Cedilla Therapeutics
- Platform, Technology and Application: TrueTarget, High Resolution Limited Proteolysis Mass Spectrometry (HR-LiP), Drug Target Validation
- Session: Drug Design and Lead Optimization Strategies Toward Novel or Difficult-to-Drug Cancer Targets
- Date and Time: Monday, April 11, 3:20 p.m. - 3:35 p.m. CDT
Poster Presentation Details
-
Abstract 1374: Discovery of MHC class I and class II neoantigens in lung cancer in needle biopsy tissue samples using an optimized high-throughput workflow
- Presenter: Marco Tognetti, Ph.D.
- Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Immunopeptidome Profiling
- Session: Tumor Antigens, Antigen Presentation, and Tumor Immunity
- Date and Time: Monday, April 11, 9:00 a.m. - 12:30 p.m. CDT
-
Abstract 3110: Identification of the phosphorylation network in PDX and corresponding organoid (PDXO) models upon targeted therapy treatment using deep phosphoproteomic analysis
- Presenter: Yuehan Feng, Ph.D.
- Collaborator: Crown Bioscience
- Platform, Technology, and Application: TrueDiscovery, Hyper Reaction Monitoring, Phosphoproteome Profiling
- Session: Patient-Derived Xenografts
- Date and Time: Tuesday, April 12, 1:30 p.m. - 5:00 p.m. CDT
-
Abstract 2924: Target identification, selectivity profiling and mechanistic insights of a CDK9 inhibitor using complementary proteomics methods
- Presenter: Yuehan Feng, Ph.D.
- Collaborator: AstraZeneca plc
- Platform, Technology and Application: TrueTarget, Limited Proteolysis Mass Spectrometry (LiP-MS), Drug Target Deconvolution
- Session: Structural and Chemical Biology
- Date and Time: Tuesday, April 12, 9:00 a.m. - 12:30 p.m. CDT
-
Abstract 3923: Ubiquitin ligases implicated as predictive biomarkers for poor outcome to immunotherapy in melanoma patients
- Presenter: Jakob Vowinckel, Ph.D.
- Collaborator: NeoGenomics Laboratories
- Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Tissue Biomarker Discovery
- Session: Proteomics, Signaling Networks, and Biomarker Discovery
- Date and Time: Wednesday, April 13, 9:00 a.m. - 12:30 p.m. CDT
-
Abstract 3920: Precise solid tumor classification through unbiased quantification of proteoforms deep into tissue leakage
- Presenter: Marco Tognetti, Ph.D.
- Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Biofluid Biomarker Discovery
- Session: Proteomics, Signaling Networks, and Biomarker Discovery
- Date and Time: Wednesday, April 13, 9:00 a.m. - 12:30 p.m. CDT
NeoGenomics Poster Collaboration Details
-
Abstract 1267: Dual approach using unbiased proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients
- NeoGenomics Presenter: Anna Juncker-Jensen, Ph.D.
- Biognosys co-authors: Nigel Beaton, Ph.D.; Kristina Beeler, Ph.D. Tobias Treiber, Ph.D.; Jakob Vowinckel, Ph.D.
- Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Tissue Biomarker Discovery
- Session: Biomarkers Predictive of Therapeutic Benefit 2
- Date and Time: Monday, April 11, 9:00 a.m. - 12:30 p.m. CDT
For the most up to date information and resources about Biognosys’ presence at AACR, visit biognosys.com/accr22.
About TrueDiscovery™
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.
About TrueTarget™
The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.
TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys.
TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification. The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005060/en/
Contact information
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KŌZĒ Stays Launches International Expansion with More Than 1,200 Properties18.11.2026 15:28:00 EET | Press release
KŌZĒ Stays announces a major international expansion, bringing its curated portfolio to more than 1,200 properties worldwide. Following eight consecutive years of rapid growth, the company is building on its established presence in Mont-Tremblant and the Laurentians to pursue a broader ambition in international hospitality. The expanded collection spans French and Swiss alpine chalets, Riviera villas near Monaco, Lake Como residences, private retreats in St. Barths and homes on Dubai’s Palm Jumeirah. Available through The KŌZĒ Collection, these properties extend the brand’s reach into some of the world’s most sought-after destinations. Canadian Roots, International Ambition “A guest who loves their stay with us in Mont-Tremblant should be able to book their next trip, whether that’s Verbier, St. Barths or Lake Como, knowing the KŌZĒ standard travels with them,” said Jeffery Khoury, Founder and CEO of KŌZĒ Stays. “That’s what this expansion is about: one name you trust, wherever you tra
Blue Yonder Announces New Leadership18.11.2026 15:03:00 EET | Press release
Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believe there is a significant additional opportunity to build on that solid foundation to expand the company’s software platform to help
AI Private Markets Platform FinBursa Appoints Angelica Tigan as Chief Revenue Officer to Drive US and Global Growth18.11.2026 15:00:00 EET | Press release
FinBursa, the intelligent front office for private markets, has appointed Angelica Tigan, a former BlackRock and eFront sales leader, as Chief Revenue Officer to lead its global commercial expansion following the launch of FinBursa 360. Based in the US, Tigan will lead sales and partnerships worldwide, with an immediate focus on the US. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118596329/en/ Angelica Tigan, based in New York City, joins FinBursa as Chief Revenue Officer Tigan brings close to two decades in private markets technology, having built, led and scaled sales teams at BlackRock (Aladdin) and eFront, with previous experience at Intralinks and Gen II Fund Services. FinBursa 360 is an all-in-one platform for private equity, private credit, real estate, venture capital and M&A advisory firms, family offices, wealth managers, placement agents and fund administrators. It brings investment CRM, deal flow and deal m
Scientist.com Launches Pharma Observatory, an Agent-First Market Intelligence Platform for Biopharma R&D18.11.2026 14:55:00 EET | Press release
Scientist.com, the leading AI-enabled R&D orchestration platform and marketplace for the life science industry, today announced the launch of Pharma Observatory, a market intelligence platform that shows biopharma teams where their programs sit in the wider market. Scientist.com helps research teams drive a project forward. Pharma Observatory places that project in context: who else is working on the same target or indication, who the likely partners and acquirers are, and what the eventual clinical trials are likely to look like. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118907460/en/ Scientist.com's Pharma Observatory brings nearly 1 billion records from ~100 public sources (ClinicalTrials.gov, FDA, USPTO, NIH, SEC) into one cross-referenced model. The public record on biopharma is huge but scattered. ClinicalTrials.gov, the FDA, SEC filings, PubMed, NIH, the USPTO and dozens of other sources each publish part of t
Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 14:36:00 EET | Press release
Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power. The funding will accelerate three areas of development: Helix HARUKA: Manufacturing and assembly of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
